scholarly journals Busulfan/Melphalan/Fludarabine (Bu/Mel/Flu) Conditioning Versus Total Body Irradiation/Thiotepa/Cyclophosphamide (HFTBI/Thio/Cy) Based Conditioning in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing CD34-Selected T-Cell Depleted Allogeneic Stem Cell Transplantation (alloSCT)

2019 ◽  
Vol 25 (3) ◽  
pp. S276-S277
Author(s):  
Jennifer S. Orozco ◽  
Patrick Hilden ◽  
Molly A. Maloy ◽  
Jeremy Pappacena ◽  
Larry W. Buie ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
T Cell ◽  
Stem Cell Transplantation ◽  
Myelodysplastic Syndrome ◽  
Allogeneic Stem Cell Transplantation ◽  
Total Body Irradiation ◽  
Myeloid Leukemia ◽  
Total Body ◽  
Acute Myeloid

Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Blood ◽  
2005 ◽  
Vol 106 (9) ◽  
pp. 3314-3321 ◽  
Author(s):  
Matthias Stelljes ◽  
Martin Bornhauser ◽  
Matthias Kroger ◽  
Joerg Beyer ◽  
Maria C. Sauerland ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Total Body Irradiation ◽  
Myeloid Leukemia ◽  
Hematopoietic Stem ◽  
Unrelated Donors ◽  
Total Body ◽  
Acute Myeloid

AbstractSeventy-one patients with acute myeloid leukemia (AML), most of them (63/71) considered ineligible for conventional allogeneic hematopoietic stem cell transplantation (HSCT), were enrolled into a phase 2 study on reduced-intensity myeloablative conditioning with fractionated 8-Gy total body irradiation (TBI) and fludarabine (120 mg/m2). Patients received mobilized peripheral blood stem cells (n = 68) or bone marrow (n = 3) from siblings (n = 39) or unrelated donors (n = 32). Thirty-six patients received a transplant in complete remission (CR) and 35 had untreated or refractory disease (non-CR). Median patient age was 51 years (range, 20-66 years). Sustained engraftment was attained in all evaluable patients. With a median follow-up of 25.9 months (range, 3.7-61.2 months) in surviving patients, probabilities of overall survival for patients who received a transplant in CR and non-CR were 81% and 21% at 2 years, respectively. Relapse-free survival rates were 78% and 16%. The cumulative incidence of nonrelapse mortality (NRM) in CR patients was 8% at 2 years and beyond but amounted to 37% at 2 years in non-CR patients. Outcome data in this poor-risk population indicate that allogeneic HSCT from related or unrelated donors with 8-Gy TBI/fludarabine conditioning is feasible with low NRM and preserved antileukemic activity in AML patients in first or later CR.

Sign in / Sign up

Export Citation Format

Share Document